Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test (NKTR)

Morsa Images/DigitalVision via Getty Images Nektar Therapeutics (NASDAQ:NKTR) has an interesting drug in its pipeline, rezpegaldesleukin (rezpeg), that has the potential to treat inflammation in a new way. The company is underway on a large study in atopic dermatitis, and recently announced it had initiated enrollment in another study in alopecia areata. This article takes…

Read More

Allianz: Strong P&C Performance Puts It Ahead Of Targets (OTCPK:ALIZF)

Cineberg These are interesting times for German insurance giant Allianz (OTCPK:ALIZY)(OTCPK:ALIZF), with higher interest rates having finally appeared after a punishing spell at their prior ultra-low levels. With a split between P&C (~45% of group operating profit), Life/Health (~35%) and Asset Management (~20%), the current macro environment throws up some challenges for Allianz, but on…

Read More